Ani Pharmaceuticals (ANIP) Consolidated Net Income (2011 - 2026)

Ani Pharmaceuticals (ANIP) has 16 years of Consolidated Net Income data on file, last reported at $29.5 million in Q1 2026.

• For the quarter ending Q1 2026, Consolidated Net Income rose 88.0% year-over-year to $29.5 million; the trailing twelve-month figure through Mar 2026 stood at $92.2 million (up 537.39% YoY), and the FY2025 full-year result was $78.3 million, up 522.94% from the prior year.
• Consolidated Net Income climbed to $29.5 million in Q1 2026, from $27.5 million in the prior quarter.
• In the past five years, Consolidated Net Income ranged from a high of $29.5 million in Q1 2026 to a low of -$24.2 million in Q3 2024.
• A 5-year average of $3.5 million and a median of $1.5 million in 2023 frame the typical range for Consolidated Net Income.
• Across the five-year window, Consolidated Net Income tumbled 23472.09% in 2022 and soared 1144.71% in 2024, its largest moves.
• Tracing ANIP's Consolidated Net Income over 5 years: stood at -$4.3 million in 2022, then jumped by 126.96% to $1.2 million in 2023, then slumped by 990.12% to -$10.3 million in 2024, then surged by 367.96% to $27.5 million in 2025, then rose by 7.15% to $29.5 million in 2026.
• Business Quant data shows ANIP's Consolidated Net Income at $29.5 million in Q1 2026, $27.5 million in Q4 2025, and $26.6 million in Q3 2025.